An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Sarah Cannon Research Institute to Present Latest Research Insights at the 2022 ASH Annual Meeting & Exposition
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Sarah Cannon Research Institute, in partnership with US Oncology Research and Ontada, is set to present over 65 abstracts at the American Society of Hematology (ASH) Annual Meeting from Dec. 10-13. This collaboration, formed in November 2022, enhances patient access to clinical trials across 250 locations in 26 states. More than 40 investigators will showcase advancements in blood cancer treatments, including innovative therapies like CAR T-Cell Therapy. Key presentations include significant studies on sickle cell disease and advanced Hodgkin lymphoma.
Positive
None.
Negative
None.
More than 40 investigators from the newly combined research network to present data from clinical trials focused on treating blood cancer and other blood disorders
NASHVILLE, Tenn. & THE WOODLANDS, Texas--(BUSINESS WIRE)--
Sarah Cannon Research Institute (SCRI), US Oncology Research (USOR), and Ontada announced that collectively more than 65 affiliated abstracts and presentations will be highlighted at the American Society of Hematology (ASH) Annual Meeting & Exposition from Dec. 10-13. The meeting brings together thought leaders from across the globe to discuss innovative research in malignant and non-malignant blood cancers.
In November 2022, McKesson and HCA Healthcare formed a joint venture combining SCRI with USOR, the research arm of The US Oncology Network (The Network). The collaboration brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the U.S. More than 40 investigators from the newly combined joint venture will present insights at this year’s Annual Meeting. Separately, Ontada, McKesson’s oncology real-world data and evidence, clinical education, and provider technology business, is also presenting a poster at the conference.
“We look forward to discussing meaningful advancements in blood cancer treatments, CAR T-Cell Therapy, immune effector cell and other novel therapies that are changing the treatment landscape for many patients,” said Howard A. “Skip” Burris, III, MD, President, SCRI. “SCRI and USOR researchers have been collaborating on pivotal research studies for years, and we are excited to see the greater impact we can make together as one team.”
A full list of presentations can be found here. Investigators highlighting research at this year’s ASH Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, US Oncology Research, as well as partners from McKesson’s The US Oncology Network and Ontada.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 600 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the U.S. Please click here to learn more about our research offerings.
About The Sarah Cannon Transplant & Cellular Therapy Network
The Sarah Cannon Transplant & Cellular Therapy Network offers adult and pediatric patients convenient and community-based access to treatments for blood cancer and blood and immune-related disorders, including hematopoietic cell transplantation and cellular therapy. Our Network of nine FACT/JACIE accredited transplant centers across the United States and United Kingdom treats more than 1,500 transplant and cellular therapy patients and 1,800 acute leukemia patient admissions annually. Emphasis is placed on providing high-quality research-based care with the opportunity for patients to enroll on innovative clinical trials. For more information about the Sarah Cannon Transplant & Cellular Therapy Network, visit sarahcannon.com.
About The US Oncology Network
Every day, The US Oncology Network (The Network) helps approximately 1,400 independent physicians deliver value-based, integrated care to patients – close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.
About Ontada
Ontada® is an oncology real-world data and evidence, clinical education and provider technology business dedicated to transforming the fight against cancer. Part of McKesson Corporation, we support science through our data, technology and channels, which accelerate innovation for life science companies, support the education of community oncology providers and advance patient care. Together with our partners, we improve the lives of cancer patients. For more information, visit ontada.com.
What is the significance of the ASH Annual Meeting for HCA?
The ASH Annual Meeting from Dec. 10-13 will feature over 65 presentations from the Sarah Cannon Research Institute and US Oncology Research, highlighting advancements in blood cancer treatments.
When was the joint venture between McKesson and HCA formed?
The joint venture combining Sarah Cannon Research Institute with US Oncology Research was formed in November 2022.
How many locations does the HCA joint venture operate in for clinical trials?
The joint venture operates in over 250 locations across 26 states in the U.S.
What key therapies will be discussed at the ASH Annual Meeting involving HCA?
The ASH Annual Meeting will discuss key therapies for blood cancer, including CAR T-Cell Therapy and other novel treatments.
Who are the leading presenters from HCA at the ASH Annual Meeting?
Leading presenters include Haydar Frangoul, MD, and Ian Flinn, MD, who will present significant findings related to blood cancer treatments.
